SCHEMBL19786280

SCHEMBL19786280

COc1ccc2c(c1)C1(C)CCCC(CO)C1CC2

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.61
CYP2C9 P11712 1/20 0.61
TSHR P16473 1/20 0.61
CYP2C19 P33261 1/20 0.61
POLA1 P09884 6/20 0.55
ALDH1A1 P00352 1/20 0.49
THRB P10828 1/20 0.49
MAPK1 P28482 1/20 0.49
NR1H2 P55055 2/20 0.41
NR1H3 Q13133 2/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
HSD17B1 P14061 1/20 0.41
RECQL P46063 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ADRB2 P07550 1/20 0.40
HTR1A P08908 1/20 0.40
ADRA2A P08913 1/20 0.40
ADRA2B P18089 1/20 0.40
SLC6A2 P23975 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19786284 0.84 POLA1 (0.53) CYP3A4CYP2C9TSHRCYP2C19POLA1
SCHEMBL267750 0.82 POLA1 (0.60) CYP3A4CYP2C9TSHRCYP2C19POLA1
SCHEMBL19786276 0.79 POLA1 (0.57) CYP3A4CYP2C9TSHRCYP2C19POLA1
SCHEMBL13165178 0.76 CYP3A4 (1.00) CYP3A4CYP2C9TSHRCYP2C19POLA1
SCHEMBL19770999 0.76 CYP3A4 (1.00) CYP3A4CYP2C9TSHRCYP2C19POLA1
SCHEMBL5530208 0.76 CYP3A4 (1.00) CYP3A4CYP2C9TSHRCYP2C19POLA1
SCHEMBL24334255 0.74 GRIN1 (0.50) CYP3A4CYP2C9TSHRCYP2C19POLA1
SCHEMBL10066628 0.74 CYP3A4 (0.66) CYP3A4CYP2C9TSHRCYP2C19POLA1
SCHEMBL14047593 0.73 POLA1 (0.73) CYP3A4CYP2C9TSHRCYP2C19POLA1
SCHEMBL806957 0.73 POLA1 (0.76) CYP3A4CYP2C9TSHRCYP2C19POLA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180015051-A1 MODULATORS OF ALPHA-DICARBONYL DETOXIFICATION AND THEIR USE FOR THE TREATMENT OF DIABETIC PATHOLOGIES BUCK INST RES AGING (US) 2018-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180015051-A1 MODULATORS OF ALPHA-DICARBONYL DETOXIFICATION AND THEIR USE FOR THE TREATMENT OF DIABETIC PATHOLOGIES TRPA1, TRPV1, TRPM2 CYP3A4 1475/4885CYP2C9 2291/4885TSHR 3381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.